The effectiveness of trospium for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.

Conclusions: Pretreatment with trospium 60 mg ER reduces the incidence and severity of CRBD in the early postoperative period. PMID: 31602966 [PubMed - as supplied by publisher]
Source: Korean Journal of Anesthesiology - Category: Anesthesiology Tags: Korean J Anesthesiol Source Type: research

Related Links:

Medtronic and Axonics are getting ready to square off in sacral neuromodulation, a fast-growing market that was monopolized by Medtronic until a month ago. Last month, Axonics won FDA approval to market its implantable rechargeable sacral neuromodulation (r-SNM) device for the treatment of fecal incontinence, and the company is expected to get FDA approval for overactive bladder and urinary retention any time now. The fecal incontinence approval includes the claim of a 15-year functional life and the ability of patients to undergo full-body MRI scans without the necessity of having the device explanted. Medtron...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
CONCLUSIONS: The indications for SNM in the German health care system can be expected to be expanded upon the chronic pelvic pain syndrome, erectile dysfunction and additional gastrointestinal conditions. Technical progress will continue to improve the risk-benefit ratio of SNM. PMID: 31139864 [PubMed - as supplied by publisher]
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
This study also found that Proteus DNA, a genus with many uropathogenic species (Drzewiecka, 2016), was more prevalent in women with OAB compared to asymptomatic controls (Curtiss et al., 2017). IC A recent study by Abernethy et al. suggested that the microbiome may play a role in IC (Abernethy et al., 2017). In this study, 16S rRNA analysis determined the microbiome of catheterized urine from women (n = 40) with IC was not dominated by a single genus and was less likely to contain Lactobacillus compared to asymptomatic women. Abernethy et al. also showed that L. acidophilus was associated with less severe scores on the ...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
As a urogynecology surgeon, Alexandra Haessler, MD, has seen firsthand the limitations of current overactive bladder (OAB) therapies. Aside from medication, the current gold standard for OAB is Medtronic's InterStim, an implantable sacral neuromodulation device that is FDA approved for the treatment of OAB as well as chronic fecal incontinence, and non-obstructive urinary retention. Haessler told MD+DI that the InterStim device works very well but it's an expensive treatment and access is limited because only a few subspecialists in any one metropolitan area are truly qualified to deliver the therapy. The InterStim is not ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Kate V. Meriwether1*, Zhenmin Lei1, Rajbir Singh2, Jeremy Gaskins3, Deslyn T. G. Hobson1 and Venkatakrishna Jala2 1Department of Obstetrics and Gynecology, University of Louisville, Louisville, KY, United States 2Department of Microbiology and Immunology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, United States 3Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, United States Interstitial cystitis/bladder pain syndrome (ICBPS) may be related to an altered genitourinary microbiome. Our aim was to compare the vaginal and urinary microbiomes b...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Conclusions and Relevance Acupuncture is an increasingly popular therapy with many potential applications in obstetrics and gynecology. A general understanding of the basic principles of acupuncture and the safety and efficacy of its practice is necessary for the general obstetrician and gynecologist to make informed recommendations to patients. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After completing this activity, the learner should be better able to identify the basic concepts of traditional Chinese medicine and how it differs from Western medicine; describe common...
Source: Obstetrical and Gynecological Survey - Category: OBGYN Tags: CME ARTICLES Source Type: research
The Neuromodulation market is rapidly growing and has become host to many medtech companies. StimGuard is the latest firm to make significant moves in the space, as it has received CE mark for a wireless neuromodulation device to treat chronic symptoms of overactive bladder. The Pompano Beach, Fla.-based company said its StimGuard would be available in Europe in the summer of 2018. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift in the field where there has only been one option for over 15 years,” Karl-Dietrich Sievert MD, PhD, professor and co-chairman o...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
MedTech Strategist working together with The Medical Alley Association for the very first time brought their premier innovation summit to Minnesota, a place now considered by many to be the global epicenter of health innovation and care. Over the two...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Source Type: blogs
ta JN Abstract Therapeutic use of GABAB receptor agonists for conditions like chronic abdominal pain, overactive bladder (OAB) and gastroesophageal reflux disease (GERD) is severely affected by poor blood-brain barrier permeability and potential side effects. ADX71441 is a novel positive allosteric modulator (PAM) of the GABAB receptor that has shown encouraging results in pre-clinical models of anxiety, pain, OAB and alcohol addiction. The present study investigates the analgesic effect of ADX71441 to noxious stimulation of the urinary bladder and colon in rats. In female Sprague-Dawley rats, systemic (i.p), but ...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Neuropharmacology Source Type: research
StimGuard said today it enrolled the 1st patient in a clinical trial of its StimGuard miniature implantable device designed to treat urinary incontinence resulting from refractory overactive bladder syndrome. The Fort Lauderdale, Fla.-based company’s system is implanted at the tibial nerve through a needle-sized introducer and uses wireless technology to stimulate the nerve and treat the symptoms of overactive bladder. “If successfully trialed, the StimGuard technology would allow neuromodulation to be offered to patients in an office setting, which has never been the case before for a permanent, long-term...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Neuromodulation/Neurostimulation StimGuard Source Type: news
More News: Anesthesia | Anesthesiology | Back Pain | Bladder Catheterization | Chloride | Fentanyl | Overactive Bladder | Overactive Bladder Syndrome | Pain | Pain Management | Study